Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19224357 | 1.00 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL12744706 | 1.00 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL24450768 | 0.78 | — | — | |
| SCHEMBL800192 | 0.75 | — | — | |
| SCHEMBL9944315 | 0.73 | — | — | |
| SCHEMBL14480127 | 0.73 | — | — | |
| SCHEMBL2612738 | 0.73 | — | — | |
| SCHEMBL16091128 | 0.73 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL25045728 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL7593328 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230147502-A1 | PHOSPHONATE LINKERS AND THEIR USE TO FACILIATE CELLULAR RETENTION OF COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147502-A1 | PHOSPHONATE LINKERS AND THEIR USE TO FACILIATE CELLULAR RETENTION OF COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220168433-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220168435-A1 | PROGRAMMABLE POLYMERIC DRUGS | SONY CORPORATION (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220160887-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-05-26 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210015930-A1 | PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10869929-B2 | Phosphonate linkers and their use to facilitate cellular retention of compounds | MERCK SHARP & DOHME CORP. (US) | 2020-12-22 | — | — | US | disclosed |
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-9884817-B2 | Auristatin derivatives and conjugates thereof | NOVARTIS AG (CH) | 2018-02-06 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170182181-A1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182181-A1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160058882-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | IMMUNOGEN, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9090629-B2 | Cytotoxic agents comprising new ansamitocin derivatives | IMMUNOGEN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147502-A1 | PHOSPHONATE LINKERS AND THEIR USE TO FACILIATE CELLULAR RETENTION OF COMPOUNDS | PHOSPHO1, SLC46A1, SLC19A1 | ALDH1A1 2710/4885 |
| US-20170182181-A1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | CD47, PLPBP, CHERP | ALDH1A1 4114/4885 |
| US-20160058882-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | MLNR, ANXA6, ANXA4 | ALDH1A1 1107/4885 |
| US-20220160887-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, NCL, PBRM1 | ALDH1A1 2462/4885 |
| US-20220168433-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, PBRM1, CHRM2 | ALDH1A1 2485/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | ALDH1A1 3212/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | ALDH1A1 4425/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | ALDH1A1 3311/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | ALDH1A1 1924/4885 |
| US-20220168435-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, PBRM1, CHRM2 | ALDH1A1 2451/4885 |
| US-20210015930-A1 | PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS | PHOSPHO1, TK1, MSN | ALDH1A1 3627/4885 |
| US-10869929-B2 | Phosphonate linkers and their use to facilitate cellular retention of compounds | PHOSPHO1, TK1, MSN | ALDH1A1 3627/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | ALDH1A1 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.